Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Insider and Institutional Ownership 70.2% of AbbVie shares are […]
Exploring China Hongqiao Group And Two More Leading Dividend Stocks yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
– Total revenues of $881 million in the first quarter
– Jakafi® net product revenues of $572 million in Q1 24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of.
China Medical System: New Drug Application of Desidustat Tablets Accepted in China – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA).
In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus.
CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.